AI Article Synopsis
- Recent advancements in treatment options for hepatocellular carcinoma (HCC) have led to increased exploration of combination therapies that pair locoregional treatments with systemic therapies for better outcomes.
- Several clinical trials have focused on trans-arterial chemoembolization (TACE), showing promising results in enhancing anti-tumor activity.
- The paper reviews current evidence and future research directions on combining TACE with various systemic treatments like antiangiogenic agents and immune checkpoint inhibitors for HCC patients.
Article Abstract
Recent years have seen the advent of novel treatment options for hepatocellular carcinoma (HCC). Given a strong biological rationale supporting this strategy, multiple studies have explored the role of combination treatments including locoregional plus systemic therapies to produce a synergistic effect and enhance antitumor activity. Among locoregional therapies, several clinical trials assessing trans-arterial chemoembolization (TACE) have been recently presented and published. In the current paper, we discuss available evidence and current and future research on combined TACE and systemic treatments, including antiangiogenic agents, immune checkpoint inhibitors, and immune-based combinations for HCC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697413 | PMC |
| http://dx.doi.org/10.3390/jpm12111788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!